Entresto associated with lowering total cost of care by $6.7 million; study

20 October 2020
money_drugs_scales_large-1-

Sacubitril-valsartan (trade name Entresto) has been proven to decrease hospitalization and reduce death due to heart failure with reduced ejection fraction (HFrEF) also known as systolic heart failure, according to a new study.

Entresto is marketed by Novartis (NOVN: VX) and generated sales of $580 million in the second quarter of 2020 for the Swiss pharma giant, up 38% year-on-year.

According to a recent study by Prime Therapeutics, members adherent to Entresto therapy for a year had reduced medical visits and expenditures. Savings associated with those visits totaled $6.7 million when comparing costs after starting Entresto to prior costs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology